Table 3 Characteristics of response and treatment

Cytologic CR/PR

7/2

Marrow response CMR/PMR

3/1

HI-N

6

HI-P

9

HI-E

5

Cytogenetic response (conventional) CR/PR

6/0

FISH response (BM) CR/PR/not done

4/1/1

FISH response (CD34, pB)CR/PR

4/2

Mitochondrial mutations CR/PR

2/1

All patients

9.5 months

Responders vs. marrow response vs. nonresponders

23 vs. 9 vs. 7 months

Median number of cycles

5(2–43)

Median number of cycles to response

2(1–9)

Dose reduction vidaza

9

75%

5

50%

4

Median dosage VPA mg/kg

25 (14–41)

Maximum VPA level (median)/μg/ml

86 (58–122)^a

Median VPA level (median)/μg/ml

68 (44–97)^a

Median time to VPA level >70 μg/ml

4 weeks^b

Patients with significant VPA side effects leading to:

13

Dose reduction/Treatment break/cessation VPA

7/5/3